Minocycline blocks acute bilirubin-induced neurological dysfunction in jaundiced Gunn rats

Neonatology

Volumn 92, Issue 4, 2007, Pages 219-226

  Geiger, Angela S ^a   Rice, Ann C ^a   Shapiro, Steven M ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Bilirubin encephalopathy; Brainstem auditory evoked potentials; Hyperbilirubinemia; Kernicterus; Neuroprotection

Indexed keywords

BILIRUBIN; MINOCYCLINE; SODIUM CHLORIDE; SULFADIMETHOXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN STEM; CONTROLLED STUDY; FEMALE; JAUNDICE; KERNICTERUS; MALE; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANIMALS, NEWBORN; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BILIRUBIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; FEMALE; JAUNDICE; KERNICTERUS; MALE; MINOCYCLINE; NEURAL CONDUCTION; RANDOM ALLOCATION; RATS; RATS, GUNN; SULFADIMETHOXINE;

RATTUS NORVEGICUS;

EID: 36248932681     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000103740     Document Type: Article

References (37)

1. Berlin CI, Morlet T, Hood LJ: Auditory neuropathy/dys-synchrony: its diagnosis and management. Pediatr Clin North Am 2003;50:331-340, vii-viii.
2. Rapin I, Gravel J: 'Auditory neuropathy': physiologic and pathologic evidence calls for more diagnostic specificity. Int J Pediatr Otorhinolaryngol 2003;67:707-728.
3. Bhutani VK, Johnson LH, Caren R: Acute bilirubin encephalopathy in healthy term and near-term newborns. Contemp Pediatr 2005;22:57-74.
4. Johnson L, Brown AK: A pilot registry for acute and chronic kernicterus in term and near-term infants. Pediatrics 1999;104:736.
5. Lin S, Wei X, Bales KR, Paul AB, Ma Z, Yan G, Paul SM, Du Y: Minocycline blocks bilirubin neurotoxicity and prevents hyperbilirubinemia-induced cerebellar hypoplasia in the Gunn rat. Eur J Neurosci 2005;22:21-27.
6. Blum D, Chtarto A, Tenenbaum L, Brotchi J, Levivier M: Clinical potential of minocycline for neurodegenerative disorders. Neurobiol Dis 2004;17:359-366.
7. Zemke D, Majid A: The potential of minocycline for neuroprotection in human neurologic disease. Clin Neuropharmacol 2004;27:293-298.
8. Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W: Minocycline as a neuroprotective agent. Neuroscientist 2005;11:308-322.
9. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM: The promise of minocycline in neurology. Lancet Neurol 2004;3:744-751.
10. Shapiro SM: Acute brainstem auditory evoked potential abnormalities in jaundiced Gunn rats given sulfonamide. Pediatr Res 1988;23:306-310.
11. Diamond I, Schmid R: Experimental bilirubin encephalopathy: the mode of entry of bilirubin- 14 C into the central nervous system. J Clin Invest 1966;45:678-689.
12. Rice AC, Shapiro SM: Biliverdin-induced brainstem auditory evoked potential abnormalities in the jaundiced Gunn rat. Brain Res 2006;1107:215-221.
13. Keppel G: Design and Analysis: A Researcher's Handbook, ed 2. Englewood Cliffs, Prentice-Hall, 1982.
14. Lagakos SW: The challenge of subgroup analyses: reporting without distorting. N Engl J Med 2006;354:1667-1669.
15. Shapiro SM, Conlee JW: Brainstem auditory evoked potentials correlate with morphological changes in Gunn rat pups. Hear Res 1991;57:16-22.
16. Conlee JW, Shapiro SM: Morphological changes in the cochlear nucleus and nucleus of the trapezoid body in Gunn rat pups. Hear Res 1991;57:23-30.
17. Shapiro SM, Hecox KE: Developmental studies of brainstem auditory evoked potentials in jaundiced Gunn rats. Brain Res 1988;469:147-157.
18. Shapiro SM, Hecox KE: Brain stem auditory evoked potentials in jaundiced Gunn rats. Ann Otol Rhinol Laryngol 1989;98:308-317.
19. Huang C-M: A comparative study of the brain stem auditory response in mammals. Brain Res 1980;184:215-219.
20. Shapiro SM: Reversible brainstem auditory evoked potential abnormalities in jaundiced Gunn rats given sulfonamide. Pediatr Res 1993;34:629-633.
21. Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, Ferrante RJ, Kristal BS, Friedlander RM: Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci USA 2003;100:10483-10487.
22. Arvin KL, Han BH, Du Y, Lin SZ, Paul SM, Holtzman DM: Minocycline markedly protects the neonatal brain against hypoxicischemic injury. Ann Neurol 2002;52:54-61.
23. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000;6:797-801.
24. Lee SM, Yune TY, Kim SJ, Park do W, Lee YK, Kim YC, Oh YJ, Markelonis GJ, Oh TH: Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma 2003;20:1017-1027.
25. Teng YD, Choi H, Onario RC, Zhu S, Desilets FC, Lan S, Woodard EJ, Snyder EY, Eichler ME, Friedlander RM: Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci USA 2004;101:3071-3076.
26. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu du C, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM: Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74-78.
27. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J: Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 2001;21:2580-2588.
28. Tikka TM, Koistinaho JE: Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 2001;166:7527-7533.
29. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J: A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 1999;96:13496-13500.
30. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J: Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998;95:15769-15774.
31. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP, Paul SM: Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 2001;98:14669-14674.
32. Fan LW, Pang Y, Lin S, Rhodes PG, Cai Z: Minocycline attenuates lipopolysaccharide-induced white matter injury in the neonatal rat brain. Neuroscience 2005;133:159-168.
33. Fan LW, Pang Y, Lin S, Tien LT, Ma T, Rhodes PG, Cai Z: Minocycline reduces lipopolysaccharide-induced neurological dysfunction and brain injury in the neonatal rat. J Neurosci Res 2005;82:71-82.
34. Fagan SC, Edwards DJ, Borlongan CV, Xu L, Arora A, Feuerstein G, Hess DC: Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection. Exp Neurol 2004;186:248-251.
35. Klein NC, Cunha BA: Tetracyclines. Med Clin North Am 1995;79:789-801.
36. Colovic M, Caccia S: Liquid chromatographic determination of minocycline in brain-toplasma distribution studies in the rat. J Chromatogr [B] 2003;791:337-343.
37. Good ML, Hussey DL: Minocycline: stain devil? Br J Dermatol 2003;149:237-239.